RxDoctor Payments Data

Emily Musgrave, DO

Family Medicine · Pendleton, INNPI 1750545786

Payments from drug & device makers

$152in general payments, 2019–2025

Across 11 payments — averaging $13.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$23
  • Nalpropion Pharmaceuticals LLC$23
  • Lilly USA, LLC$22
  • Inspire Medical Systems, Inc.$19
  • Sanofi-aventis U.S. LLC$16
  • GSK$14
  • plus $35 from 3 others

What the payments were for

  • Food & beverage$152100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck2$23
Nalpropion Pharmaceuticals LLC1$23
Lilly USA, LLC2$22
Inspire Medical Systems, Inc.1$19
Sanofi-aventis U.S. LLC1$16
GSK1$14
AstraZeneca1$12
Johnson & Johnson1$11
Novo Nordisk1$11

How this compares

$152 in reported general payments places this provider in the 30th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$86,364
Medicare patients
205
Services billed
894

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide56$118,683
JardianceEmpagliflozin71$82,923
EliquisApixaban84$72,435
TrulicityDulaglutide52$69,740
JanuviaSitagliptin Phosphate36$57,197
MyrbetriqMirabegron25$22,361
MounjaroTirzepatide20$21,422
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$18,576
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,426
UbrelvyUbrogepant13$13,198
TradjentaLinagliptin12$12,178
Bydureon BciseExenatide Microspheres13$10,793
Mirabegron ErMirabegron11$8,692
Atorvastatin Calcium563$5,953
Omeprazole263$4,310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$11$118,68356 claims
Lilly USA, LLCTrulicity, Mounjaro$22$91,16272 claims
MerckJanuvia$23$57,19736 claims
GSKTrelegy Ellipta$14$14,42620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Pendleton

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →